Ovation ScienceOVATF Current Ratio is 0.03 as of Mar. 2026, which is 98% below its 10-year median of 1.25. The stock has 4 warning signs investors should review. Among 998 Drug Manufacturers companies, Ovation Science ranks worse than 99% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ovation Science's current ratio for the quarter that ended in Mar. 2026 was 0.03.
Ovation Science has a current ratio of 0.03. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Ovation Science has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Ovation Science's Current Ratio or its related term are showing as below:
OVATF'
s Current Ratio Range Over the Past 10 Years
Min: 0.02 Med: 1.25 Max: 39.96
Current: 0.03
During the past 9 years, Ovation Science's highest Current Ratio was 39.96. The lowest was 0.02. And the median was 1.25.
OVATF's Current Ratio is ranked worse than 99% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs OVATF: 0.03
Ovation Science (OTCPK:OVATF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ovation Science Current Ratio Related Terms
Ovation Science Current Ratio Historical Data
* Premium members only.
The historical data trend for Ovation Science's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovation Science Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ovation Science's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ovation Science's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovation Science (OVATF) has a Current Ratio of 0.03 as of Mar. 2026. This is 98% below median its historical median of 1.25. Over the past decade, Ovation Science's Current Ratio has ranged from 0.02 to 39.96. According to the industry distribution chart, Ovation Science ranks #988 out of 998 companies in the Drug Manufacturers industry, placing it in the top 99%.
Is Ovation Science's Current Ratio too high?
Ovation Science's current Current Ratio of 0.03 is 98% below median its 10-year median of 1.25. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 39.96. The Drug Manufacturers industry median Current Ratio is 2.00. Ovation Science's value of 0.03 is 98.5% below this industry median. Based on the distribution chart, Ovation Science ranks #988 out of 998 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ovation Science's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ovation Science ranks #988 out of 998 companies for Current Ratio. This places Ovation Science in the lower half of its industry. The industry median Current Ratio is 2.00. Ovation Science's value of 0.03 is 98.5% below this benchmark. Historically, Ovation Science's own Current Ratio has ranged from 0.02 to 39.96 over the past decade. While the company's 10-year median is 1.25 vs. the industry median of 2.00, Ovation Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ovation Science's current Current Ratio of 0.03 is 98.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovation Science's current Current Ratio is 0.03, which is 98% below median its own 10-year median of 1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovation Science stock overvalued right now?
Based on GuruFocus' analysis, Ovation Science (OVATF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.04 — trading 16.7% above its estimated fair value. The current Current Ratio is 0.03, which is 98% below median its 10-year median of 1.25 and 98.5% below the Drug Manufacturers industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ovation Science (OVATF), the current Current Ratio is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ovation Science Inc. is a Canada-based company mainly engaged in the business of providing topical and transdermal cannabis products under the Ovation brand label, utilizing patented Invisicare delivery technology. The Company operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare, a patented polymer-based technology for topical and transdermal skin care products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVATF has been successfully added to your 